Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853676 | 0.88 | MEN1 (0.65) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL6416822 | 0.87 | MEN1 (0.53) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL9018657 | 0.86 | MEN1 (0.71) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL10617946 | 0.84 | NPC1 (0.57) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL14871553 | 0.84 | KMT2A (0.59) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL1429699 | 0.82 | MEN1 (0.65) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL27833966 | 0.82 | ALDH1A1 (0.64) | MEN1KMT2AHTTMAPTALDH1A1 | |
| 4-Nitroaniline SCHEMBL3978656 | 0.81 | ALDH1A1 (0.56) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL23748585 | 0.80 | MEN1 (0.70) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL10923174 | 0.80 | NPSR1 (0.73) | MEN1KMT2AHTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921770-B2 | 2-Phenyliminothiazolines, their preparation method and anti-rice blast agent containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-07-26 | — | — | US | disclosed |
| EP-1311160-A4 | 2-PHENYLIMINOTHIAZOLINES, THEIR PREPARATION METHOD AND ANTI-RICE BLAST AGENT CONTAINING THE SAME | KOREA INST SCI & TECH (KR) | 2004-04-21 | — | — | EP | disclosed |
| US-20030203950-A1 | 2-Phenyliminothiazolines, their preparation method and anti-rice blast agent containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-10-30 | — | — | US | disclosed |
| EP-1311160-A1 | 2-PHENYLIMINOTHIAZOLINES, THEIR PREPARATION METHOD AND ANTI-RICE BLAST AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002013611-A1 | 2-PHENYLIMINOTHIAZOLINES, THEIR PREPARATION METHOD AND ANTI-RICE BLAST AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2002-02-21 | — | — | WO | disclosed |
| US-4558158-A | Process for the production of 4-(trialkylammonium)-acetoacetarylides | LONZA LTD. (CH) | 1985-12-10 | — | — | US | disclosed |
| US-4552983-A | Process for the production of 4-(trialkylammonium)-acetoacetarylides | LONZA LTD. (CH) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203950-A1 | 2-Phenyliminothiazolines, their preparation method and anti-rice blast agent containing the same | TYR, SYPL1, SSBP1 | MEN1 131/4885KMT2A 2739/4885HTT 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.